Dr. Lisa Crossley reports

RELIQ HEALTH TECHNOLOGIES, INC. ANNOUNCES INCREASE TO UP TO $6 MILLION TO PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT

Reliq Health Technologies Inc. has made an increase to its previously announced $4-million brokered private placement of units, initially announced on Sept. 27, 2023. The offering has been increased due to significant demand and is now targeted for gross proceeds of up to $6-million (previously $4-million) through the issuance of up to 15 million units of the company at 40 cents per unit. Each unit will continue to consist of one common share and one transferable share purchase warrant. Each warrant shall be exercisable into one additional common share of the company for a period of 30 months from the closing date (as defined below) at an exercise price of 52 cents. All references to currency herein are to Canadian dollars.

The units will be offered by way of a best efforts private placement pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106, Prospectus Exemptions, and on a private placement basis pursuant to other exemptions from the prospectus requirements, in all provinces of Canada (except Quebec), and has now been extended to certain jurisdictions outside of Canada. The securities of the company issued pursuant to the listed issuer financing exemption will be freely tradeable equity securities not subject to any hold period under applicable Canadian securities laws. There is an offering document related to the offering that can be accessed under the company's profile on SEDAR+ and on the company's website. Prospective investors should read this offering document before making an investment decision.

Pursuant to its engagement with PI Financial Corp., upon closing of the offering, the company shall: (i) pay to PI a cash commission equal to 8.0 per cent of the aggregate gross proceeds of the offering, payable in cash; (ii) issue to PI non-transferable warrants of the company, exercisable at any time prior to the date that is 30 months from the closing date to acquire that number of units equal to 8.0 per cent of the number of units issued under the offering, at an exercise price equal to the warrant share price, subject to adjustment in certain events.

The net proceeds raised from the issuance of the units will be used to fund growth initiatives, for general corporate and working capital requirements, or for other corporate purposes, as described in the offering document.

The offering is scheduled to close on or around Oct. 5, 2023, and is subject to certain conditions, including, but not limited to, receipt of all necessary approvals, including the approval of the TSX Venture Exchange.

About Reliq Health Technologies Inc.

Reliq is a rapidly growing global health care technology company that specializes in developing innovative virtual care solutions for the multibillion-dollar health care market. Reliq's powerful iUGO Care platform supports care co-ordination and community-based virtual health care. iUGO Care allows complex patients to receive high-quality care at home, improving health outcomes, enhancing the quality of life for patients and families, and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and emergency room (ER) visits. Reliq trades on the TSX Venture Exchange under the symbol RHT, on the OTC as RQHTF and on the Frankfurt Stock Exchange under the WKN: A2AJTB.

We seek Safe Harbor.